DermTech Falls After Cigna Tells Bloomberg No Change To Genetic Testing Coverage

Laboratory Test Tubes

Image Source: Unsplash

Cigna (CI) last night told Bloomberg in an emailed statement said: "There has not been a change to our genetic testing coverage policies related to cutaneous melanoma.

The only change to our policies is to indicate that we follow NCCN guidelines, which do not support the use of this test for this indication."

DermTech (DMTK) shares rallied yesterday after Craig-Hallum said that Cigna has become the first insurer to cover the company's Pigmented Lesion Assay genetic test.

The stock in premarket trading is down 7% to $42.50.

 

Disclaimer: TheFly's news is intended for informational purposes only and does not claim to be actionable for investment decisions. Read more at  more

How did you like this article? Let us know so we can better customize your reading experience.

Comments

Leave a comment to automatically be entered into our contest to win a free Echo Show.
Frank J. Williams 2 weeks ago Member's comment

The only change to our policies is to indicate that we follow NCCN guidelines, which do not support the use of this test for this indication." This is factually incorrect.

Adam Reynolds 2 weeks ago Member's comment

Are you sure?

Frank J. Williams 2 weeks ago Member's comment

Yes, see the news release re DMTK on 1.12.2021.